Latest Conference Articles

March 7th 2013, 2:49pm

PER® Miami Breast Cancer Conference

An interview with Debu Tripathy, MD, summarizing noteworthy results from the 2012 ASCO Annual Meeting and SABCS, including clinical studies in local, adjuvant, and metastatic breast cancer therapies.

March 6th 2013, 3:33pm

Gastrointestinal Cancers Symposium (ASCO GI)

Capecitabine produces similar local disease control with lower toxicity versus gemcitabine when combined with radiotherapy following induction chemotherapy in patients with locally advanced pancreatic cancer.

March 5th 2013, 7:49am

Gastrointestinal Cancers Symposium (ASCO GI)

FOLFOXIRI plus bevacizumab improved progression-free survival and response rates with a modest increase in side effects compared with FOLFIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer.

March 4th 2013, 1:13pm

Gastrointestinal Cancers Symposium (ASCO GI)

Complete neoadjuvant treatment may represent a well-tolerated alternative to the current standard treatment sequence of adjuvant chemotherapy following chemoradiation and surgery.

February 18th 2013, 11:22am

Genitourinary Cancers Symposium (ASCO GU)

William C. Huang, MD, from the New York University Langone Medical Center, discusses findings from a SEER database analysis that compared surveillance to surgical resection in elderly patients with small renal masses.

February 18th 2013, 9:31am

Genitourinary Cancers Symposium (ASCO GU)

The 2013 Genitourinary Cancers Symposium was held at the Rosen Shingle Creek, Orlando, Florida, from February 14-16.

February 16th 2013, 5:55pm

Genitourinary Cancers Symposium (ASCO GU)

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the earlier administration of treatment with sipuleucel-T for men with prostate cancer.

February 16th 2013, 12:58pm

Genitourinary Cancers Symposium (ASCO GU)

Axitinib did not demonstrate superiority over sorafenib as first-line therapy for patients with metastatic renal cell carcinoma, on the endpoint of progression-free survival.

February 16th 2013, 11:49am

Genitourinary Cancers Symposium (ASCO GU)

Tivozanib did not show a significant difference in overall survival when compared with sorafenib in patients with renal cell carcinoma who received up to one prior line of therapy excluding targeted agents.

February 16th 2013, 11:16am

Genitourinary Cancers Symposium (ASCO GU)

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses an updated analysis of the phase III ALSYMPCA trial that examined radium-223 dichloride in patients who have CRPC with bone metastases.

February 16th 2013, 8:35am

Genitourinary Cancers Symposium (ASCO GU)

Combination targeted therapy did not significantly extend progression-free survival compared with single-agent bevacizumab in patients with advanced renal cell carcinoma.

February 15th 2013, 1:20pm

Genitourinary Cancers Symposium (ASCO GU)

Howard I. Scher, MD, from Memorial Sloan-Kettering Cancer Center, discusses the impact of corticosteroids on outcomes for men with metastatic castration-resistant prostate cancer receiving treatment with enzalutamide.

February 15th 2013, 1:20pm

Genitourinary Cancers Symposium (ASCO GU)

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the overall survival results from the phase III TIVO-1 study that compared tivozanib to sorafenib in patients with renal cell carcinoma.

February 15th 2013, 1:20pm

Genitourinary Cancers Symposium (ASCO GU)

The addition of dasatinib to standard therapy with docetaxel failed to improve survival and most other clinical endpoints in men with metastatic castration-resistant prostate cancer in the phase III READY trial.

February 15th 2013, 9:24am

Genitourinary Cancers Symposium (ASCO GU)

An updated interim analysis of the COU-AA-302 trial upholds the benefits of abiraterone acetate in mildly symptomatic or asymptomatic patients with progressive mCRPC untreated with prior chemotherapy.

February 15th 2013, 9:03am

Genitourinary Cancers Symposium (ASCO GU)

Use of corticosteroids had a negative impact on outcomes with enzalutamide treatment as well as placebo treatment in men with metastatic castrate resistant prostate cancer.

February 15th 2013, 8:08am

Genitourinary Cancers Symposium (ASCO GU)

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the third interim analysis of the COU-AA-302 trial that examined abiraterone acetate before chemotherapy in mCRPC.

February 14th 2013, 4:05pm

Genitourinary Cancers Symposium (ASCO GU)

Abdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer.

February 14th 2013, 12:07pm

Genitourinary Cancers Symposium (ASCO GU)

Small renal masses identified in elderly patients can be safely managed by surveillance and maintain the same mortality risk as those who undergo surgery, suggesting that surgery could be avoided altogether in many patients.

February 14th 2013, 9:33am

Genitourinary Cancers Symposium (ASCO GU)

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the implications of a large study looking at the detection of prostate cancer using prostate biopsies.